Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

Completed · Phase 2

Conditions studied: Atypical Hemolytic Uremic Syndrome

In brief

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).

Key facts

Study ID

NCT00844545

Run by

Alexion Pharmaceuticals, Inc.

People needed

16

Starts

2009-05-01

Expected to finish

2013-07-01

Last updated by the study team

2015-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• TTP, (defined as ADAMTS-13 activity <5%) from an historical observation (prior to initiation of plasma therapy) or as tested at the screening visit by the central laboratory
• Malignancy within 5 years of screening
• Typical HUS (Shiga toxin +)
• Known HIV infection
• Identified drug exposure-related HUS.
• Infection-related HUS
• HUS related to bone marrow transplant
• HUS related to vitamin B12 deficiency
• Renal function status requiring chronic dialysis
• Patients with a confirmed diagnosis of sepsis
• Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease
• Pregnancy or lactation
• Unresolved meningococcal disease
• Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome
• Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study
• Patients who have received previous treatment with eculizumab
• Patients receiving IVIG within 8 weeks or Rituximab therapy within 12 weeks of screening.
• Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors or tacrolimus are excluded unless: [1] part of an established post-transplant anti-rejection regime, [2] patient has confirmed anti-CFH antibody requiring immunosuppressive therapy, and [3] dose of such medications have been unchanged for at least 4 weeks prior to the screening period or [4] patient is experiencing an acute aHUS relapse immediately after transplant
• Patients receiving Erythrocyte Stimulating Agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period, or a washout period of at least 2 weeks from the last dose of ESA therapy.
• Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior to screening and throughout the entire trial.
• Hypersensitivity to eculizumab, to murine proteins or to one of the excipients

Where it is running

• Study site — Atlanta, Georgia, United States
• Study site — Fort Wayne, Indiana, United States
• Study site — New York, New York, United States
• Study site — New York, New York, United States
• Study site — Grapevine, Texas, United States
• Study site — Houston, Texas, United States
• Study site — Innsbruck, Austria
• Study site — Bordeaux, France
• Study site — Lyon, France
• Study site — Nantes, France
• Study site — Paris, France
• Study site — Quimper, France
• Study site — Saint-Priest-en-Jarez, France
• Study site — Tours, France
• Study site — Aachen, Germany
• Study site — Essen, Germany
• Study site — Newcastle, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.